Skip to main content

Advertisement

Table 3 Infants with congenital diaphragmatic hernia in the Neonatal Research Network

From: Milrinone in congenital diaphragmatic hernia – a randomized pilot trial: study protocol, review of literature and survey of current practices

  2011 2012 Average Range among centers
Total CDH admissions 175 162 169  
 CDH ≥ 36 0/7 week PMA 142 133 138 (81%)  
 Inhaled NO in the preoperative period among CDH ≥ 36 0/7 weeks PMA 53 55 54 (39%) 0–100%
Other medications used in the preoperative period among CDH ≥ 36 0/7 weeks PMA
 Milrinone 17 29 23 (17%) 0–70%
 Sildenafil 27 21 24 (17%) 0–73%
 Flolan ® (inhaled epoprostenol) 8 9 9 (6%) 0–68% a
 Flolan ® (intravenous epoprostenol) 6 3 5 (3%) 0–25% a
 Alprostadil (intravenous PGE1) 6 5 6 (4%) 0–50%
 Epinephrine 2 0 1 (1%) 0–25% a
ECMO among all CDH 59 56 58 (34%) 8–87%
ECMO among CDH ≥ 36 0/7 weeks PMA 51 48 50 (36%) 9–59%
Survival to discharge
 - All CDH 111 117 114 (68%) 40–100%
 - CDH ≥ 36 0/7 weeks PMA 94 101 98 (71%) 53–100%
Concern regarding use of iNO in CDH Yes – 8; No – 11b  
Primary physician managing pulmonary vasodilator therapy Surgeons – 4; Neonatologists – 10; Joint (surgeons + neonatologists – 3); Pediatric Intensivists – 1  
  1. a These medications were used in one center only within the Network
  2. b One center with two hospitals had a different response at each hospital